Emerging molecular classifications and therapeutic implications for gastric cancer

Cancer Communications

Table 2 Completed phase III clinical trials of targeted therapies for advanced GCs

Target	Clinical trial	Inhibitor	Combination treatment	No. of cases	Primary endpoint	Reference
HER2	ToGA	Trastuzumab	Capecitabine/5-fluorouracil + cisplatin	594	OS (13.8 months)	[36]
HER2	TyTAN	Lapatinib	Paclitaxel	261	OS (11 months)	[37]
EGFR	EXPAND	Cetuximab	Capecitabine/capecitabine + cisplatin	904	PFS (4.4 months)	[38]
EGFR	REAL-3	Panitumumab	Best supportive care	463	PFS (2 months)	[39]
VEGFR	AVAGAST	Bevacizumab	Capecitabine + cisplatin	774	OS (12.1 months)	[40]
VEGFR	REGARD	Ramucirumab	Best supportive care	355	PFS (5.2 months)	[41]

HER2 erb-b2 receptor tyrosine kinase 2, EGFR epidermal growth factor receptor, VEGFR vascular endothelial growth factor receptor, OS overall survival, PFS progression-free survival

ISSN: 2523-3548